274 related articles for article (PubMed ID: 31122207)
1. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP
BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
[TBL] [Abstract][Full Text] [Related]
3. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O
Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622
[TBL] [Abstract][Full Text] [Related]
4. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
5. 8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy.
Voutsadakis IA
J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32987805
[TBL] [Abstract][Full Text] [Related]
6. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.
Pourdehnad M; Truitt ML; Siddiqi IN; Ducker GS; Shokat KM; Ruggero D
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11988-93. PubMed ID: 23803853
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
8. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.
Satheesha S; Cookson VJ; Coleman LJ; Ingram N; Madhok B; Hanby AM; Suleman CA; Sabine VS; Macaskill EJ; Bartlett JM; Dixon JM; McElwaine JN; Hughes TA
Mol Cancer; 2011 Feb; 10():19. PubMed ID: 21320304
[TBL] [Abstract][Full Text] [Related]
9. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells.
Ochnik AM; Peterson MS; Avdulov SV; Oh AS; Bitterman PB; Yee D
Neoplasia; 2016 Feb; 18(2):100-10. PubMed ID: 26936396
[TBL] [Abstract][Full Text] [Related]
10. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
11. Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon.
Streicher KL; Yang ZQ; Draghici S; Ethier SP
Oncogene; 2007 Mar; 26(14):2104-14. PubMed ID: 17001308
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
13. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
14. Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines.
Yang ZQ; Albertson D; Ethier SP
Cancer Genet Cytogenet; 2004 Nov; 155(1):57-62. PubMed ID: 15527903
[TBL] [Abstract][Full Text] [Related]
15. The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.
Ding M; Van der Kwast TH; Vellanki RN; Foltz WD; McKee TD; Sonenberg N; Pandolfi PP; Koritzinsky M; Wouters BG
Mol Cancer Res; 2018 Apr; 16(4):682-695. PubMed ID: 29453322
[TBL] [Abstract][Full Text] [Related]
16. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
[TBL] [Abstract][Full Text] [Related]
18. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.
Garcia MJ; Pole JC; Chin SF; Teschendorff A; Naderi A; Ozdag H; Vias M; Kranjac T; Subkhankulova T; Paish C; Ellis I; Brenton JD; Edwards PA; Caldas C
Oncogene; 2005 Aug; 24(33):5235-45. PubMed ID: 15897872
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase PPM1G regulates protein translation and cell growth by dephosphorylating 4E binding protein 1 (4E-BP1).
Liu J; Stevens PD; Eshleman NE; Gao T
J Biol Chem; 2013 Aug; 288(32):23225-33. PubMed ID: 23814053
[TBL] [Abstract][Full Text] [Related]
20. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
